Recombinant SARS-CoV-2 Nucleocapsid Protein derived from E.coli
Product Description
Specifications
| Size | 100 ug, 500 ug, 1000 ug |
|---|---|
| Species | SARS-CoV-2 |
| Accession Number | QHD43423 |
| Protein Name / Synonyms | SARS-CoV-2 N protein, nucleocapsid protein |
| Expressed Region | Met1 - Ala419 |
| Expression System | E. coli |
| Tag | N-terminal histidine tag |
| Purification | His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC) |
| Purity | >95 % |
| Purity Determined By | SDS-PAGE under reducing conditions and visualized by Coomassie blue staining |
| Molecular Weight (kDa) | ∼50 kDa |
| Format | Liquid |
| Formulation | 15 mM Na2HPO4, 5 mM NaH2PO4, 0.25 M NaCl, pH 7.5 |
| Concentration (lot specific) | Lot specific (see the label on the vial), determined by Bradford protein assay. |
| Estimated Lead Time | 1-2 business days |
| Shipping Type | Blue ice |
| Storage | -20°C |
A Vojdani and D Kharrazian. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. Clin Immunol. 217, 108480 (2020).
M Casasanta, et al. Structural Insights of the SARS-CoV-2 Nucleocapsid Protein. Comput Struct Biotechnol J. 18, 2174-2184 (2020).
Casasanta M, et al. Microchip-based structure determination of low-molecular weight proteins using cryo-electron microscopy. Nanoscale (2021).
Vojdani A, et al. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol (2021).
Yu J, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike protein is blocked by factor D inhibition.?Blood. 2020 Sep 2;blood.2020008248 (2020).
Woodruff M., Ramonell R., Nguyen D., et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nature Immunology volume 21, pages 1506-1516 (2020)
Species:
Human
Sample Type:
Conditioned Media (HEK Expressed, coupling to microspheres)
Write Your Own Review